JP2016094424A5 - - Google Patents

Download PDF

Info

Publication number
JP2016094424A5
JP2016094424A5 JP2015229465A JP2015229465A JP2016094424A5 JP 2016094424 A5 JP2016094424 A5 JP 2016094424A5 JP 2015229465 A JP2015229465 A JP 2015229465A JP 2015229465 A JP2015229465 A JP 2015229465A JP 2016094424 A5 JP2016094424 A5 JP 2016094424A5
Authority
JP
Japan
Prior art keywords
seq
region
amino acid
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015229465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016094424A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016094424A publication Critical patent/JP2016094424A/ja
Publication of JP2016094424A5 publication Critical patent/JP2016094424A5/ja
Pending legal-status Critical Current

Links

JP2015229465A 2009-10-14 2015-11-25 EphA3に対する抗体 Pending JP2016094424A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25166809P 2009-10-14 2009-10-14
US61/251,668 2009-10-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012534368A Division JP2013508292A (ja) 2009-10-14 2010-10-14 EphA3に対する抗体

Publications (2)

Publication Number Publication Date
JP2016094424A JP2016094424A (ja) 2016-05-26
JP2016094424A5 true JP2016094424A5 (https=) 2016-10-06

Family

ID=43499991

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012534368A Pending JP2013508292A (ja) 2009-10-14 2010-10-14 EphA3に対する抗体
JP2015229465A Pending JP2016094424A (ja) 2009-10-14 2015-11-25 EphA3に対する抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012534368A Pending JP2013508292A (ja) 2009-10-14 2010-10-14 EphA3に対する抗体

Country Status (11)

Country Link
US (2) US8664365B2 (https=)
EP (1) EP2488554B1 (https=)
JP (2) JP2013508292A (https=)
CN (1) CN102666589B (https=)
AU (1) AU2010313621C1 (https=)
CA (1) CA2777068C (https=)
DK (1) DK2488554T3 (https=)
ES (1) ES2743558T3 (https=)
PL (1) PL2488554T3 (https=)
PT (1) PT2488554T (https=)
WO (1) WO2011053465A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011235867B2 (en) * 2010-04-01 2015-12-03 Kalobios Pharmaceuticals, Inc. EphA3 antibodies for the treatment of multiple myeloma
WO2011160132A2 (en) * 2010-06-18 2011-12-22 Kalobios Pharmaceuticals, Inc. Detection of epha3 as a marker of the presence of a solid tumor
JP2014527054A (ja) 2011-08-12 2014-10-09 カロバイオス ファーマシューティカルズ インコーポレイティッド 骨髄内の異常血管系上に発現したEphA3を標的とすることによる、血液増殖性疾患を処置する方法
PH12021552742A1 (en) 2013-08-01 2022-05-23 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
US20170145103A1 (en) 2015-11-23 2017-05-25 Five Prime Therapeutics, Inc. Predicting response to cancer treatment with fgfr2 inhibitors
WO2018053032A1 (en) * 2016-09-13 2018-03-22 Humanigen, Inc. Epha3 antibodies for the treatment of pulmonary fibrosis
SG10202112636SA (en) 2017-05-16 2021-12-30 Five Prime Therapeutics Inc Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
EP3758751A4 (en) 2018-02-28 2021-11-17 Wuxi Biologics Ireland Limited. MONOCLONAL ANTIBODIES AGAINST HUMAN LAG-3, METHOD OF MANUFACTURING AND USING THEREOF
IL291937A (en) * 2019-10-09 2022-06-01 Council Queensland Inst Medical Res Direct link to epha3 and its uses
TW202134278A (zh) * 2019-11-08 2021-09-16 美商胡曼尼根公司 用於治療腫瘤之epha3導向car-t細胞
EP4232470A4 (en) * 2020-10-23 2025-01-15 Atreca, Inc. ANTIBODIES AGAINST CORONAVIRUS SARS-COV-2
CN118055945A (zh) * 2021-08-06 2024-05-17 韩国生命工学研究院 新型抗epha2嵌合抗原受体和表达其的免疫细胞

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
EP0590030B1 (en) 1991-06-21 2004-09-29 The Walter and Eliza Hall Institute of Medical Research A receptor-type tyrosine kinase [human eph/elk-like kinase - hek] and use thereof
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
NO175798C (no) 1992-07-22 1994-12-07 Sinvent As Fremgangsmåte og anordning til aktiv stöydemping i et lokalt område
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP2322644A1 (en) 2000-06-28 2011-05-18 GlycoFi, Inc. Methods for producing modified glycoproteins
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
CA2478297C (en) 2002-03-19 2013-05-14 Plant Research International B.V. Optimizing glycan processing in plants
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
JP4782700B2 (ja) * 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
EP1778726A4 (en) 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
US8222253B2 (en) * 2004-10-23 2012-07-17 Case Western Reserve University Peptide and small molecule agonists of EphA and their uses
US20060134098A1 (en) 2004-11-16 2006-06-22 Kalobios, Inc. Immunoglobulin variable region cassette exchange
US8211648B2 (en) 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2008060092A1 (en) 2006-11-17 2008-05-22 Sang Yun Park Rotative force generator
AU2008226905C1 (en) 2007-03-08 2014-11-06 Humanigen, Inc. EphA3 antibodies for the treatment of solid tumors
CL2008002782A1 (es) 2007-09-21 2009-07-31 Genentech Inc Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
AU2010221159B2 (en) 2009-03-06 2015-11-26 Humanigen, Inc. Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3

Similar Documents

Publication Publication Date Title
JP2016094424A5 (https=)
JP2013508292A5 (https=)
JP2015520758A5 (https=)
JP2016536361A5 (https=)
JP2015534579A5 (https=)
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
JP2018506277A5 (https=)
EP4435009A3 (en) Claudin6 antibodies and methods of treating cancer
JP2018534933A5 (https=)
JP2017535257A5 (https=)
JP2020536109A5 (https=)
JP2017507652A5 (https=)
JP2017529838A5 (https=)
JP2011514150A5 (https=)
RU2019111722A (ru) Антитела против siglec-15 и способы их применения
JP2015503909A5 (https=)
JP2014511179A5 (https=)
JP2016188209A5 (https=)
JP2009521496A5 (https=)
JP2017515815A5 (https=)
JP2014158469A5 (https=)
FI3805268T3 (fi) Vasta-aine joka sitoo ErbB-2:ta ja ErbB-3:a
RU2016100892A (ru) Антитела против tweakr и их применение
HRP20210778T1 (hr) Neutralizacija inhibitornih putova u limfocitima
RU2015144105A (ru) Антитела к гепсидину и их применения